GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Itacitinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms GRAVITAS-301
- Sponsors Incyte Corporation
- 20 Jul 2017 The first patient has been treated in this trial, according to an Incyte Corporation media release.
- 22 Jun 2017 Status changed from not yet recruiting to recruiting.
- 04 May 2017 According to an Incyte Corporation media release, this program is expected begin in 2017.